Abstract
PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Current Pharmaceutical Design
Title:Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Volume: 18 Issue: 30
Author(s): Sukhvir Chand, Nisha Mehta, Malkeet Singh Bahia, Anshuman Dixit and Om Silakari
Affiliation:
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Abstract: PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Export Options
About this article
Cite this article as:
Chand Sukhvir, Mehta Nisha, Singh Bahia Malkeet, Dixit Anshuman and Silakari Om, Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651625
DOI https://dx.doi.org/10.2174/138161212802651625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrochemical MIP-Sensors for Drugs
Current Medicinal Chemistry Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update
Coronaviruses Optimized and Comparative Antioxidant Assays and Its Applications in Herbal and Synthetic Drug Analysis as an Antioxidants
Mini-Reviews in Medicinal Chemistry The Molecular Mechanisms of Glucocorticoids-Mediated Neutrophil Survival
Current Drug Targets Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Mycoplasma pneumoniae: Does it have a Role in Asthma Pathogenesis?
Current Pediatric Reviews Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Recent Developments in the Synthesis of Bicyclic Condensed Pyrimidinones
Current Organic Chemistry Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma
Mini-Reviews in Medicinal Chemistry Small Molecule Inhibitors of Lck: The Search for Specificity within a Kinase Family
Mini-Reviews in Medicinal Chemistry Effect of Boswellia serrata Extract Microcapsule Against Ulcerative Colitis in Mice
The Natural Products Journal Prevention of Allergic Disease Development and Symptoms by Food Factors
Current Pharmaceutical Design Inflammation in Asthma Pathogenesis: Role of T Cells, Macrophages, Epithelial Cells and Type 2 Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design The Long and Winding Road to Convert an Antimicrobial Compound into an Antimicrobial Drug: An Overview from a Medicinal Chemistry Point of View
Current Organic Chemistry Biological Nitration of Arachidonic Acid
Current Vascular Pharmacology Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Endogenous Acetylcholine Controls the Severity of Polymicrobial Sepsisassociated Inflammatory Response in Mice
Current Neurovascular Research